CD5+ Relapsed/Refractory Hematopoietic Malignancies
1 clinical trials · Condition
◉ Watch CD5+ Relapsed/Refractory Hematopoietic Malignancies
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies (NCT04767308) | Huazhong University of Science and Technology | 2021-03-01 |
Track CD5+ Relapsed/Refractory Hematopoietic Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.